Advancing Structured Benefit-Risk Assessment in FDA Review
Duke-Margolis Center for Health Policy
Contact InformationMonika Schneider
Advances in cancer care have resulted in significant improvement in patient outcomes, but spending remains high, and there are concerns about the value that treatment provides. New oncology payment models have been helping providers transform care from fee-for-service payments to reimbursement that rewards better care and value. To date, there have been several models introduced and implemented that focus on reducing costs and improving the quality of care for patients. However, value-based reimbursement of drugs has been difficult to incorporate into provider models. The goal of this workshop is to identify steps that could enhance the success of value-based payment models for cancer care, with an emphasis on payments to drug manufacturers that better align with provider alternative payment approaches, aiming to improve outcomes and avoid inefficient and low-value spending for cancer patients.